Brixton Biosciences Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
28
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$999K
- Investors
-
12
Brixton Biosciences General Information
Description
Developer of a biomedical neuromodulation therapy designed to sustain pain relief and support mobility. The company offers a proprietary neural cooling implant technology, featuring minimally invasive delivery, long-duration effects, and academic validation, enabling patients with chronic or acute musculoskeletal pain to regain function and reduce discomfort.
Contact Information
Website
www.brixtonbio.comCorporate Office
- 1000 Massachusetts Avenue
- Suite 101
- Cambridge, MA 02138
- United States
Corporate Office
- 1000 Massachusetts Avenue
- Suite 101
- Cambridge, MA 02138
- United States
Brixton Biosciences Timeline
Brixton Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 25-Oct-2024 | $999K | Completed | Clinical Trials - General | ||
| 3. Later Stage VC (Series B) | 14-May-2024 | Completed | Clinical Trials - General | |||
| 2. Grant | 27-Sep-2022 | $252K | $8M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 15-Nov-2019 | $8M | $8M | Completed | Clinical Trials - General |
Brixton Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Brixton Biosciences Comparisons
Industry
Financing
Details
Brixton Biosciences Competitors (47)
One of Brixton Biosciences’s 47 competitors is Xalud Therapeutics, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
| Centrexion Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
| Cerecin | Venture Capital-Backed | Broomfield, CO | ||||
| MannKind | Formerly VC-backed | Danbury, CT |
Brixton Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Brixton Biosciences Patents
Brixton Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4504215-A1 | Compositions of and methods for a cold slurry having hyaluronic acid | Pending | 11-Feb-2022 | ||
| EP-4504215-A4 | Compositions of and methods for a cold slurry having hyaluronic acid | Pending | 11-Feb-2022 | ||
| US-20260256507-A1 | Compositions of and methods for a cold slurry having hyaluronic acid | Pending | 11-Feb-2022 | ||
| AU-2023217092-A1 | Compositions of and methods for a cold slurry having hyaluronic acid. | Pending | 11-Feb-2022 | ||
| EP-4352430-A1 | Methods of creating a slurry using liposome emulsions | Pending | 11-Jun-2021 | A61K9/107 |
Brixton Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Brixton Biosciences Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel Physicians Fund | Angel Group | Minority | ||
| Eckuity | Growth/Expansion | Minority | ||
| FemHealth Ventures | Venture Capital | Minority | ||
| PV Capital Management | Family Office | Minority | ||
| Schooner Capital | Growth/Expansion | Minority |
Brixton Biosciences FAQs
-
When was Brixton Biosciences founded?
Brixton Biosciences was founded in 2019.
-
Where is Brixton Biosciences headquartered?
Brixton Biosciences is headquartered in Cambridge, MA.
-
What is the size of Brixton Biosciences?
Brixton Biosciences has 28 total employees.
-
What industry is Brixton Biosciences in?
Brixton Biosciences’s primary industry is Drug Discovery.
-
Is Brixton Biosciences a private or public company?
Brixton Biosciences is a Private company.
-
What is Brixton Biosciences’s current revenue?
The current revenue for Brixton Biosciences is .
-
How much funding has Brixton Biosciences raised over time?
Brixton Biosciences has raised $41M.
-
Who are Brixton Biosciences’s investors?
Angel Physicians Fund, Eckuity, FemHealth Ventures, PV Capital Management, and Schooner Capital are 5 of 12 investors who have invested in Brixton Biosciences.
-
Who are Brixton Biosciences’s competitors?
Xalud Therapeutics, Centrexion Therapeutics, Cristal Therapeutics, Cerecin, and MannKind are some of the 47 competitors of Brixton Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
